Hetero Labs Limited Valacyclovir Export Data — India (DGFT 2022–2026)

Name: Hetero Labs Limited Valacyclovir Export Records India — #2 Exporter, 251 Shipments, $12.6M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-05-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Valacyclovir

India Pharmaceutical Trade Intelligence

$93.2M113 Suppliers70 CountriesHS 30049099

ExportsIndia → UNITED STATES87.2%India → CANADA4.0%

ImportsUNITED STATES → India$11.1K GERMANY → India$3.4K

#1 Supplier: MYLAN LABORATORIES #1 Buyer: MYLAN PHARMACEUTICALS

Hetero Labs Limited — Valacyclovir Exporter #2 | $12.6M Trade Value | TransData Nexus | TransData Nexus

Hetero Labs Limited — Valacyclovir Exporter Profile

Indian Pharmaceutical Exporter · #2 for Valacyclovir · $12.6M export value · DGFT Verified

Hetero Labs Limited is the #2 Indian exporter of Valacyclovir with $12.6M in export value and 251 verified shipments. Hetero Labs Limited holds a 13.5% market share in Valacyclovir exports across 12 countries. The company exports 46 pharmaceutical products worth $319.3M across 18 therapeutic categories.

Hetero Labs Limited — Valacyclovir Export Profile: Buyers & Destinations

Hetero Labs Limited Valacyclovir export treemap — buyers and destination countries | TransData Nexus

Where Does Hetero Labs Limited Export Valacyclovir?

Country	Value	Shipments	Share
UNITED STATES	$5.9M	121	55.6%
UNITED STATES OF AMERICA	$2.5M	49	23.1%
SWEDEN	$1.3M	38	12.0%
SAUDI ARABIA	$341.7K	10	3.2%

Who Are the Top Buyers of Valacyclovir from Hetero Labs Limited?

Buyer	Country	Value	Orders
TO THE ORDER OF	SWEDEN	$5.3M	116
XXMBEXXPHAXXACEXXICAXX IXX	UNITED STATES OF AMERICA	$2.5M	49
CAMBER PHARMACEUTICALS INC	UNITED STATES	$989.3K	23
CAMBER PHARMACEUTICALS INC.	UNITED STATES	$350.0K	7
SAUDI AMAROX FOR INDUSTRY COMPANY	SAUDI ARABIA	$286.7K	7
CAMBER LABORATORIES SDN BHD	MALAYSIA	$148.1K	3
CAMBER PHARMACEUTICALS, INC.	PHILIPPINES	$106.0K	3
DHL EXEL SUPPLY CHAIN (SWEDEN) AB	SWEDEN	$94.1K	3
TO THE ORDER	SWEDEN	$74.2K	4
XXNDOXXPTYXXTD	AUSTRALIA	$50.0K	1

Hetero Labs Limited supplies Valacyclovir to 21 buyers globally. The largest buyer is TO THE ORDER OF (SWEDEN), followed by XXMBEXXPHAXXACEXXICAXX IXX (UNITED STATES OF AMERICA) and CAMBER PHARMACEUTICALS INC (UNITED STATES). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.

What Valacyclovir Formulations Does Hetero Labs Limited Export?

Product Description / Formulation	Value	Shipments
VALACYCLOVIR TABLET	$3.6M	72
VALACYCLOVIR 1000MG TABLETS (1X30'S)	$750.0K	15
VALACYCLOVIR 500MG TABLETS	$450.0K	9
VALACYCLOVIR 1000MG TABLET 90S	$450.0K	9
VALACICLOVIR BLUEFISH (VALACYCLOVIR 500MG TABLET 6S)	$403.6K	9
VALACYCLOVIR 500MG TABLETS (1X30'S)	$400.0K	8
VALACYCLOVIR TABLETS	$350.0K	7
VALACYCLOVIR 1000MG TABLETS (1X90'S)	$300.0K	6
VALACYCLOVIR 500MG TABLETS (1X90'S)	$300.0K	6
VALACYCLOVIR 500MG TABLET 90S	$300.0K	6

Hetero Labs Limited exports 61 distinct Valacyclovir formulations including tablets, capsules, syrups, and combination drugs. The top formulation is VALACYCLOVIR TABLET with 72 shipments worth $3.6M.

How Does Hetero Labs Limited Compare to Nearest Valacyclovir Exporters?

Exporters ranked immediately above and below #2 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
2	HETERO LABS LIMITED ★	$12.6M	251	12	$50.0K
1	MYLAN LABORATORIES LIMITED	$3.1M	62	3	$50.0K
3	AUROBINDO PHARMA LTD	$2.0M	41	2	$50.0K

Hetero Labs Limited ranks #2 among 113 Indian Valacyclovir exporters. Average shipment value of $50.0K compared to the market average of $187.0K. The closest competitors by value are MYLAN LABORATORIES LIMITED and AUROBINDO PHARMA LTD.

Which Indian Ports Ship Valacyclovir Exports?

Port	Shipments	% Share
DELHI AIR CARGO ACC (INDEL4)	571	22.5%
SAHAR AIR CARGO ACC (INBOM4)	495	19.5%
SAHAR AIR	366	14.4%
DELHI AIR	311	12.3%
Delhi Air	110	4.3%
Bombay Air	107	4.2%
BANGALORE ICD (INWFD6)	60	2.4%
NHAVA SHEVA SEA (INNSA1)	54	2.1%

Geopolitical & Trade Policy Impact on Hetero Labs Limited's Valacyclovir Exports

The current geopolitical climate presents both challenges and opportunities for Hetero Labs Limited. The Israel-Iran tensions have led to increased risks in the Red Sea shipping routes, prompting major shipping lines to implement 'Emergency Risk Surcharges' ranging from $250 to $500 per TEU. This escalation in shipping costs directly impacts Indian pharmaceutical exporters like Hetero, potentially eroding profit margins and necessitating strategic adjustments in logistics and pricing strategies.

Conversely, the U.S.-China trade tensions have created openings for Indian pharmaceutical companies. The U.S. has imposed tariffs as high as 245% on APIs from certain countries, leading to a reshoring of pharmaceutical manufacturing. Indian firms, including Hetero, have responded by investing in U.S. facilities, with outbound foreign direct investment estimated between $500-700 million during the partial FY 2025-26. This strategic move not only circumvents tariffs but also strengthens Hetero's presence in the lucrative U.S. market.

The recent India-European Union Free Trade Agreement (FTA), concluded in January 2026, eliminates tariffs on Indian pharmaceuticals entering the EU. This development enhances Hetero's competitiveness in the European market, providing a significant boost to its export potential. However, compliance with the EU's Falsified Medicines Directive remains imperative, necessitating stringent quality controls and traceability measures to maintain market access.

Hetero Labs Limited — Regulatory Compliance & Quality Standards

Regulatory compliance is paramount for Hetero's sustained success in international markets. In October 2025, the U.S. Food and Drug Administration (FDA) issued a Form 483 to Hetero's Nakkapalli facility in Andhra Pradesh, citing six major compliance lapses, including quality control deficiencies and improper documentation practices. Such observations can jeopardize Hetero's ability to supply APIs and antiretroviral drugs to the U.S. market, underscoring the critical need for rigorous adherence to Good Manufacturing Practices (GMP) and prompt corrective actions to address regulatory concerns.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Valacyclovir shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Hetero Labs Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
4.Verified Records: This page is backed by 251 individual customs records matching Hetero Labs Limited exporting Valacyclovir, covering 61 formulations to 13 countries via 21 buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 70+ countries, 197+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Valacyclovir

Valacyclovir

Hetero Labs Limited — Valacyclovir Exporter Profile

Hetero Labs Limited — Valacyclovir Export Profile: Buyers & Destinations

Where Does Hetero Labs Limited Export Valacyclovir?

Who Are the Top Buyers of Valacyclovir from Hetero Labs Limited?

What Is India's Total Valacyclovir Export Value and How Much Does Hetero Labs Limited Contribute?

What Is the Average Shipment Value for Hetero Labs Limited's Valacyclovir Exports?

How Does Hetero Labs Limited Compare to Other Indian Valacyclovir Exporters?

What Valacyclovir Formulations Does Hetero Labs Limited Export?

Regulatory Requirements: Exporting Valacyclovir to Key Markets

United States — FDA

How Does Hetero Labs Limited Compare to Nearest Valacyclovir Exporters?

Which Indian Ports Ship Valacyclovir Exports?

What Other Antivirals Products Does Hetero Labs Limited Export?

Geopolitical & Trade Policy Impact on Hetero Labs Limited's Valacyclovir Exports

Hetero Labs Limited — Regulatory Compliance & Quality Standards

About Hetero Labs Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Valacyclovir Export Data from Hetero Labs Limited

Valacyclovir Stats

Company Overview

Top Products by Hetero Labs Limited

Related Analysis

Need Detailed Export Data?

Data Source